^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
RNAscope™ ISH Probe High Risk HPV

Company:
Bio-Techne
Type:
CE Marked
Related tests:
Evidence

News

3d
Bio-Techne files patent infringement lawsuit against molecular instruments (Bio-Techne Press Release)
"Bio-Techne Corporation...announced that it has taken legal action in the Unified Patent Court in Europe to halt the infringement of its patented RNAscope® ISH technology by Molecular Instruments, Inc."
Corporate lawsuit • Patent
|
RNAscope™ ISH Probe High Risk HPV
19d
Bio-Techne surpasses 10,000 peer-reviewed publications citing RNAscope technology (Bio-Techne Press Release)
"Bio-Techne Corporation...announced that Advanced Cell Diagnostics (ACD), part of Bio-Techne's spatial biology division, has surpassed 10,000 peer-reviewed publications referencing the use and application of RNAscope™ ISH technology."
Clinical data
|
RNAscope™ ISH Probe High Risk HPV
5ms
CSF1 expression in xanthogranulomatous epithelial tumor/keratin-positive giant cell-rich tumor. (PubMed, Hum Pathol)
Our findings provide additional evidence that the CSF1/CSF1R pathway is involved in the pathogenesis of XGET/KPGCT. These findings suggest a possible role for CSF1R inhibition in the treatment of unresectable or metastatic XGET/KPGCT.
Journal
|
CSF1 (Colony stimulating factor 1)
|
CSF1 expression
|
RNAscope™ ISH Probe High Risk HPV
6ms
Immunoglobulin light chain transcript detection by ultrasensitive RNA in situ hybridization for B-cell lymphoma diagnosis. (PubMed)
IGK/L double-negative cells were detected in 1 PMBCL, 2 MGZL, and all classical HL, while monotypic IgLC expression appeared to be a hallmark in nodular lymphocyte-predominant HL. IgLC-RNAsc demonstrates to be a powerful tool in B-cell lymphoma diagnosis, above all in challenging cases with limited tumor cell content, ensuring in situ investigations on mechanisms of Ig regulation across lymphoma entities.
Journal
|
RNAscope™ ISH Probe High Risk HPV
9ms
Bio-Techne ends collaboration program with Akoya to automate RNAscope on the Phenocycler Fusion (Bio-Techne Press Release)
"Bio-Techne...announced that the company will end their collaboration with Akoya Biosciences to co-develop an automated RNAscope™ workflow for use with the PhenoCycler®-Fusion System...Bio-Techne will continue to support its customers utilizing RNAscope assays in conjunction with Opal™ reagents and PhenoImager™ HT systems purchased from Akoya."
Licensing / partnership
|
RNAscope™ ISH Probe High Risk HPV
12ms
Bio-Techne announces launch of kappa and lambda RNAScope ISH Probes as analyte specific reagents (ASRS) for the detection of immunoglobulin kappa and lambda light chains mRNA (Bio-Techne Press Release)
"Bio-Techne...announced the launch of two new RNAscope™ in situ Hybridization Probes Kappa and Lambda as analyte specific reagents (ASRs) for the detection of immunoglobulin kappa and lambda light chains mRNA in B-cells...RNAscope ISH Probes Kappa and Lambda are designed to detect immunoglobulin kappa and lambda light chains mRNA. RNAscope probes are visualized with the highly sensitive RNAscope ISH detection reagents, which are compatible with FFPE tissue."
Launch
|
RNAscope™ ISH Probe High Risk HPV
1year
Bio-Techne and Lunaphore establish strategic partnership to develop the first fully automated same-slide spatial multiomics solution (Bio-Techne Press Release)
"Bio-Techne...and Lunaphore...announced a strategic partnership to develop the first fully automated spatial multiomics workflow with same-slide hyperplex detection of protein and RNA biomarkers. Designed to provide ultimate flexibility in panel design, the solution will allow researchers to easily combine well-characterized antibodies with gold-standard RNAscope™ in situ hybridization probes to illuminate changes in cell phenotypes and functional states across a wide range of diseases."
Licensing / partnership
|
RNAscope™ ISH Probe High Risk HPV
1year
Bio-Techne to showcase innovative cancer research, cell therapy and manufacturing tools at AACR 2023 conference (Bio-Techne Press Release)
"Bio-Techne Corporation...announced it will present its portfolio of products and solutions to advance cancer research and enable cell and gene therapy development and manufacturing at the upcoming annual meeting of the American Association for Cancer Research (AACR), taking place April 14-19 in Orlando, Florida."
Clinical data
|
RNAscope™ ISH Probe High Risk HPV
over1year
In Situ Hybridization for HTLV-1 Is an Accessible and Reliable Tool for Identification of Adult T-Cell Leukemia/ Lymphoma in Clinical Practice (USCAP 2023)
The detection of HTLV-1 using RNAScopeTM is a clinically accessible method that offers excellent sensitivity and specificity for making real-time diagnosis of ATLL and allows reliable separation from non-HTLV-1 T-cell lymphomas. This novel technique is practical and should be utilized in the diagnostic algorithm of T-cell lymphomas, except in samples that underwent decalcification.
Clinical
|
CD4 (CD4 Molecule)
|
CD4 positive
|
RNAscope™ ISH Probe High Risk HPV
over1year
Utility of GLI1 RNA in Situ Hybridization in Distinguishing Between Cutaneous Basal Cell Carcinoma and Other Epithelial Neoplasms (USCAP 2023)
With careful evaluation, GLI1 RNA CISH is highly sensitive (100%) and specific (97%) in distinguishing between BCC and non-follicular epithelial tumors. The specificity is lower (38%) among basaloid follicular tumors, likely reflecting the importance of Hh pathway signaling in the normal development of hair follicles. Overall, detection of GLI1 RNA by CISH may be a useful tool for more precise classification of difficult basaloid neoplasms, particularly in the setting of small biopsy specimens, metaplastic differentiation, or metastatic disease.
SMO (Smoothened Frizzled Class Receptor) • GLI1 (GLI Family Zinc Finger 1)
|
SMO mutation • GLI1 expression
|
RNAscope™ ISH Probe High Risk HPV
almost2years
Bio-Techne Announces Launch of the CE-IVD RNAscope ISH Probe High Risk HPV Assay for Head and Neck Cancer (Bio-Techne Press Release)
"Bio-Techne...announced the European launch of the CE-IVD marked RNAscope ISH Probe High Risk HPV, intended for use in patients diagnosed with oropharyngeal squamous cell carcinoma (OPSCC) to aid in the identification of high-risk human papillomavirus (HPV)."
Launch Europe
|
RNAscope™ ISH Probe High Risk HPV